Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2842 - Programmed death ligand-1overexpression is a poor prognostic factor for Human papillomavirus-positive tonsillar squamous cell carcinoma

Date

10 Sep 2017

Session

Poster display session

Presenters

Mi Jung Kwon

Citation

Annals of Oncology (2017) 28 (suppl_5): v372-v394. 10.1093/annonc/mdx374

Authors

M.J. Kwon1, M. Hong2, S.Y. Kang3

Author affiliations

  • 1 Pathology, Hallym University Sacred Heart Hospital, 431-796 - anyang/KR
  • 2 Pathology, Kangnam Sacred Heart Hospital, 134-701 - seoul/KR
  • 3 Pathology, Samsung Medical Center Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
More

Resources

Abstract 2842

Background

Programmed death-ligand 1 (PD-L1) plays a key role for immune evasion, contributing to carcinogenesis and tumor progression. Tonsillar squamous cell carcinomas (TSCCs) are the most common human papillomavirus (HPV)-associated oropharyngeal cancers and they frequently present with locally advanced diseases and cervical metastases, which are associated with poor prognoses. Recent studies have reported the close association between PD-L1 and HPV in head and neck SCCs. However, its clinical and prognostic significances in TSCCs remain controversial.

Methods

Immunohistochemical analysis of PD-L1 was performed in 79 formalin-fixed paraffin-embedded blocks of surgically resected specimens. Peptide nucleic acid-based HPV chip test was used for detection of HPV.

Results

PD-L1 expression was observed in 19 cases (24.1%), and clinicopathological features such as invasion to base of tongue, lymphatic invasion, infiltrative tumor border, younger age (

Conclusions

PD-L1 overexpression may predict a poor prognosis and a high risk of recurrence in TSCC patients, especially in HPV-positive tonsil cancers, implying PD-L1 could be potent candidates for a new prognostic and predictive biomarker in tonsil cancers.

Clinical trial identification

none of clinical trial

Legal entity responsible for the study

none

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.